Royalty Pharma plc
RPRX
$53.25
$1.553.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.38% | 2.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.38% | 2.08% | |||
| Cost of Revenue | -954.73% | 90.40% | |||
| Gross Profit | 38.27% | 0.29% | |||
| SG&A Expenses | -17.83% | 60.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -100.72% | 45.31% | |||
| Operating Income | 76.29% | -16.20% | |||
| Income Before Tax | 31.56% | -19.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 31.56% | -19.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -22.48% | 9.16% | |||
| Net Income | 37.57% | -25.68% | |||
| EBIT | 76.29% | -16.20% | |||
| EBITDA | 76.03% | -16.17% | |||
| EPS Basic | 75.11% | -42.26% | |||
| Normalized Basic EPS | 818.12% | -75.14% | |||
| EPS Diluted | 74.88% | -42.09% | |||
| Normalized Diluted EPS | 620.36% | -67.80% | |||
| Average Basic Shares Outstanding | -21.44% | 28.74% | |||
| Average Diluted Shares Outstanding | 0.15% | -0.65% | |||
| Dividend Per Share | 6.82% | 0.00% | |||
| Payout Ratio | -0.19% | 0.33% | |||